Abstract
A patient with adult-onset vitelliform dystrophy received intravitreal injections of bevacizumab in one eye. During 4 months of follow-up, spectral domain optical coherence tomography (SD-OCT) showed a progressive decrease of yellowish deposits and complete resolution of subretinal fluid at the last followup. Despite the good anatomic outcome, the patient reported a mild decrease in visual acuity and persistent metamorphopsia. The clinical course and the correlation between the fundus findings and the morphologic information from SD-OCT data are described.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Fluorescein Angiography
-
Follow-Up Studies
-
Fourier Analysis
-
Humans
-
Injections
-
Macular Degeneration / diagnosis*
-
Macular Degeneration / drug therapy*
-
Male
-
Middle Aged
-
Tomography, Optical Coherence / methods*
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Visual Acuity
-
Vitreous Body
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Vascular Endothelial Growth Factor A
-
Bevacizumab